Core Insights - Deerfield Management Company disclosed a significant purchase of Celcuity shares, acquiring 980,470 shares valued at approximately $80.60 million in the fourth quarter of 2026 [1][2] - The total value of Deerfield's position in Celcuity reached $170.95 million at the end of the quarter, reflecting an increase of $134.72 million from the previous quarter, driven by both new purchases and share price appreciation [2] Company Overview - Celcuity Inc. is a biotechnology firm focused on precision oncology, utilizing its CELsignia platform and a pipeline of targeted therapeutics to identify specific cellular drivers of cancer for personalized treatment [5] - The company has a market capitalization of $5.3 billion and reported a net income of -$162.72 million over the trailing twelve months [4] Product and Pipeline - Celcuity's lead drug candidate, Gedatolisib, targets the PI3K and mTOR signaling pathways, which are crucial for cancer growth, by blocking multiple components simultaneously [9] - The FDA has accepted Celcuity's new drug application for Gedatolisib in hormone receptor positive, HER2 negative advanced breast cancer, granting it priority review with a decision date set for July 17, 2026 [10] Market Performance - Celcuity's shares have surged over 1,040% in the past year, significantly outperforming the S&P 500's gain of approximately 19% during the same period [7] - The company is expected to release its upcoming quarterly report soon, and as of September 30, it reported having around $455 million in cash and short-term investments, sufficient to fund operations through the next year [11]

Company Overview - Celcuity is a clinical-stage biotechnology company focused on precision oncology, utilizing its proprietary CELsignia platform to identify abnormal cellular signaling in cancer cells and guide targeted therapy development [6] - The company's pipeline includes innovative diagnostic and therapeutic candidates, with a strategic emphasis on addressing unmet needs in breast and ovarian cancer [6] - As of February 17, 2026, Celcuity shares were priced at $107.32, with a market capitalization of $4.97 billion and a net income of ($162.72 million) [4][8] Recent Developments - On February 17, 2026, Boxer Capital Management, LLC disclosed a purchase of 135,000 shares of Celcuity, valued at an estimated $11.10 million based on quarterly average pricing [1][2] - This acquisition increased Boxer Capital's stake in Celcuity to represent 4.9% of the fund's 13F reportable assets, with the reported value of the position rising to $22.44 million, up $18.00 million from the prior quarter [2][3] - Celcuity shares have experienced a significant one-year price change of 741.1%, outperforming the S&P 500 by 721.3 percentage points [3] Competitive Position - Celcuity develops molecularly targeted therapies for cancer, including the CELsignia diagnostic platform and the investigational drug Gedatolisib for breast cancer treatment [8] - The company’s competitive advantage lies in its integrated approach to diagnostics and therapeutics, supported by partnerships such as its license agreement with Pfizer for Gedatolisib [9]